<DOC>
	<DOCNO>NCT01673191</DOCNO>
	<brief_summary>There need find effective therapy diabetic patient develop macular edema cataract surgery .</brief_summary>
	<brief_title>A 3-Month Clinical Trial Assess Safety Efficacy OZURDEX® Intraocular Implant Patients With Diabetes Mellitus</brief_title>
	<detailed_description>The objective study assess safety efficacy OZURDEX® intraocular implant patient diabetes mellitus , develop macular edema cataract surgery</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patient diagnosis Diabetes Mellitus , Type I II . Patient experience development macular edema follow cataract surgery least one eye . Patient cataract surgery within 90 day prior screen visit . Patient significant ocular disease study eye , include glaucoma . Patient active infection study eye . Patient uncontrolled systemic illness ( i.e. , uncontrolled blood pressure , uncontrolled diabetes mellitus ) . Patient experience significant increase intraocular pressure follow prior treatment topical intravitreal steroidal medication . Patient receive OZURDEX® implant study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>